HealthMore in Health→
Pancreatic cancer vaccine points to earlier interception
Key Takeaways
- Nature Medicine highlighted a phase 1 study of an off-the-shelf vaccine targeting mutant KRAS.
- The vaccine safely produced durable T cell responses in healthy people at high risk of pancreatic cancer.
- The strategy focuses on precursor-stage disease, where the immune environment may be less suppressive than in established PDAC.
DE
DT Editorial Team··via nature.com
